search
Back to results

RESIST! Blood-flow Restriction Resistance Training for Improving Insulin Sensitivity in Type 2 Diabetes (RESIST)

Primary Purpose

Type 2 Diabetes

Status
Recruiting
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Blood-flow restriction resistance training
Classical resistance training
Sponsored by
German Diabetes Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Type 2 Diabetes focused on measuring Insulin sensitivity, Blood flow restriction training, Muscle hypertrophy, Muscle Strength, Hypoxia

Eligibility Criteria

30 Years - 69 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Male and female, age between ≥ 30 and ≤ 69 years
  • Individuals with type 2 diabetes
  • BMI: 19-40 kg/m²

Exclusion Criteria:

  • Acute infections in the last 2 weeks
  • Weight fluctuations (> 10% in the last 6 month)
  • Therapy with Glitazone, Beta blocker, Insulin
  • Malignant cancer
  • Heart diseases (angina pectoris, myocardial infarction, acute myocarditis or pericarditis, cardiac wall aneurysms/ stenose, untreated hypotension or hypertension, aortic stenosis, stroke, cardiac insufficiency, NYHA-class ≥II, heart arrhythmia, disturbances of blood circulation in extremities, venous insufficiency, varicose veins)
  • Diabetic neuropathy
  • Respiratory disease (COPD, Gold grade ≥II)
  • Serious heart, kidney or liver disease: - New York Heart Association-Classification (NYHA) stage ≥ II - creatinine ≥ 1.6 mg / dl - Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≥ two-fold upper reference value
  • Anemia (Hb <12g / l), blood donation in the last 3 month
  • Disease of the immune system (leucocytes <5000/μl)
  • Application of immunomodulatory agents (Glucocorticoids, Antihistamine, Acetylsalicylic acid)
  • Application of antithrombotic agents (Anticoagulant)
  • Blood clotting disorders (abnormally levels of thrombocytes [<150.000, >450.000 ± 50 ], Partial thromboplastin time (PTT) [26-36 s ± 5 s], Quick [70-120% ± 10%]) or wound healing
  • Thyroid disease (untreated hypothyroidism or hyperthyroidism, treatment with thiamazol)
  • Epilepsy
  • Application of drugs which can manipulate the thermoregulation (Antipsychotic)
  • Rosacea
  • Vitamine supplement (with the las 4 weeks)
  • Cigarettes (or non-smokers <1 year) alcohol consumption (men> 30 g / d, women> 20 g / d), drug abuse
  • Severe psychiatric illness or addiction
  • Risk for/ or HIV or Hepatitis B or C
  • Shift work or anormal circadian rhythm
  • Muscle diseases, orthopedic restrictions
  • Hypersensitivity to local anaesthetic
  • Pregnancy, lactation
  • Metallic and magnetic implants (for example, mechanical heart valves, joint prostheses, clip after vascular surgery, middle and inner ear implants or fresh dental implants)
  • Claustrophobia
  • Hypohidrosis
  • Participation in another intervention study within the last 3 month

Sites / Locations

  • German Diabetes CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Blood-flow restriction resistance training

Classical resistance training

Arm Description

Resistance training with low loads (15-30% RM) in combination with a brief occlusion of venous blood flow using a tourniquet while exercising.

Resistance training with high loads (60-80% RM).

Outcomes

Primary Outcome Measures

Change in insulin sensitivity by blood-flow restriction or classical resistance training
By using hyperinsulinemic-euglycemic clamp technique, changes in the M-value (mg x kg-1 x min-1) will be measured. The m-value represent the glucose infusion rate at a defined level of hyperinsulinemia during a glucose clamp test. The hyperinsulinemic-euglycemic clamp technique will thus be implicated to assess changes in insulin sensitivity before and after 12 weeks of resistance training.

Secondary Outcome Measures

Changes in skeletal muscle mass by blood-flow restriction or classical resistance training
Cross-sectional area (cm2) from quadriceps will be measured by MRI imaging technique to evaluate changes in muscle diameter ("hypertrophy") before and after 12 weeks of resistance training.

Full Information

First Posted
December 10, 2019
Last Updated
June 10, 2023
Sponsor
German Diabetes Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04222231
Brief Title
RESIST! Blood-flow Restriction Resistance Training for Improving Insulin Sensitivity in Type 2 Diabetes
Acronym
RESIST
Official Title
Metabolic Effects of a New Resistance Training in Individuals With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 28, 2019 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
March 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
German Diabetes Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The study aims to investigate the metabolic and cardiovascular effects of classical resistance training with high loads and blood-flow restricted training (BFRT) with low loads in individuals with type 2 diabetes over 12 weeks.
Detailed Description
Type 2 diabetes (T2D) is characterized by an increasing insensitivity of muscle, fat and liver cells to the hormone insulin. About 9% of the global population is affected by this condition and mortality risk is twice as high in individuals with diabetes compared to similar-aged people without diabetes. Muscle is of particular importance for glucose homeostasis, since in healthy people it accounts for 80-90% of postprandial insulin-stimulated glucose disposal. After cellular uptake of glucose by the specialized glucose transporter 4 (GLUT4), glucose is phosphorylated and stored as glycogen. In individuals with obesity or T2D, the capacity for insulin to facilitate glucose uptake and glycogen synthesis is impaired. This reduced response of a given insulin concentration to exert its biological effect is termed insulin resistance. Subsequent diminished insulin secretion due to β-cell failure results in fasting hyperglycemia and overt diabetes. Importantly, muscle insulin resistance is the initial defect occurring in the development of T2D and precedes the clinical development of the disease by up to 20 years. Thus, the preservation of skeletal muscle function is essential for people with T2D who have an increased risk of sarcopenia. On the one hand high intensity resistance training (HIT) with 80 % one-repetition maximum (%1-RM) is a well-recognized strategy to improve muscle strength and glycemic control for individuals with T2D, on the other hand elderly or obese people may not be able to tolerate these high loads. Blood flow restriction training (BFRT) with low loads (20-30% 1-RM) has consistently demonstrated comparable effects to HIT and seems to be a promising alternative to increase muscle function. During the BFRT the muscle becomes hypoxic due to a brief occlusion of venous blood flow using a tourniquet while exercising. Consequently metabolites like lactate, growth hormone (GH) and insulin like growth factor (IGF-1) are released and result in muscle hypertrophy through activating the collagen synthesis and the recruitment of satellite cells. Furthermore cell swelling based on venous blood pooling, reactive hyperemia and metabolite accumulation has been shown to increase protein synthesis by activating the mammalian Target of Rapamycin Complex 1 (mTORC1) pathway. Also, BFRT increases the level of reactive oxygen species (ROS) which may lead to higher glucose uptake during exercise. Last but not least higher threshold motor units (fast twitch fibers) are recruited due to hypoxia and metabolite accumulation. Although there is a significant inverse relationship between muscle strength and the risk of cardiovascular mortality, cardiovascular adaptations to resistance training are under-explored and poorly understood. The study therefore aims to investigate the metabolic and cardiovascular effects of BFRT with low loads in individuals with T2D.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Insulin sensitivity, Blood flow restriction training, Muscle hypertrophy, Muscle Strength, Hypoxia

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Blood-flow restriction resistance training
Arm Type
Experimental
Arm Description
Resistance training with low loads (15-30% RM) in combination with a brief occlusion of venous blood flow using a tourniquet while exercising.
Arm Title
Classical resistance training
Arm Type
Experimental
Arm Description
Resistance training with high loads (60-80% RM).
Intervention Type
Other
Intervention Name(s)
Blood-flow restriction resistance training
Intervention Description
Training program: After 10 minutes of warm-up the participant performs three exercises with BFRT for the lower extremities. The intensity is about 15-30% of 1-RM.
Intervention Type
Other
Intervention Name(s)
Classical resistance training
Intervention Description
Training program: After warm-up the participant performs three exercises for lower body. The intensity is about 60-80% of 1-RM.
Primary Outcome Measure Information:
Title
Change in insulin sensitivity by blood-flow restriction or classical resistance training
Description
By using hyperinsulinemic-euglycemic clamp technique, changes in the M-value (mg x kg-1 x min-1) will be measured. The m-value represent the glucose infusion rate at a defined level of hyperinsulinemia during a glucose clamp test. The hyperinsulinemic-euglycemic clamp technique will thus be implicated to assess changes in insulin sensitivity before and after 12 weeks of resistance training.
Time Frame
Before and after 12 weeks of training (intervention)
Secondary Outcome Measure Information:
Title
Changes in skeletal muscle mass by blood-flow restriction or classical resistance training
Description
Cross-sectional area (cm2) from quadriceps will be measured by MRI imaging technique to evaluate changes in muscle diameter ("hypertrophy") before and after 12 weeks of resistance training.
Time Frame
Before and after 12 weeks of training (intervention)
Other Pre-specified Outcome Measures:
Title
Changes in skeletal muscle strength by blood-flow restriction or classical resistance training
Description
Isometric and submaximal strength tests (kg) will be performed to measure changes in muscle strength before and after 12 weeks of resistance training.
Time Frame
Before and after 12 weeks of training (intervention)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male and female, age between ≥ 30 and ≤ 69 years Individuals with type 2 diabetes BMI: 19-40 kg/m² Exclusion Criteria: Acute infections in the last 2 weeks Weight fluctuations (> 10% in the last 6 month) Therapy with Glitazone, Beta blocker, Insulin Malignant cancer Heart diseases (angina pectoris, myocardial infarction, acute myocarditis or pericarditis, cardiac wall aneurysms/ stenose, untreated hypotension or hypertension, aortic stenosis, stroke, cardiac insufficiency, NYHA-class ≥II, heart arrhythmia, disturbances of blood circulation in extremities, venous insufficiency, varicose veins) Diabetic neuropathy Respiratory disease (COPD, Gold grade ≥II) Serious heart, kidney or liver disease: - New York Heart Association-Classification (NYHA) stage ≥ II - creatinine ≥ 1.6 mg / dl - Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≥ two-fold upper reference value Anemia (Hb <12g / l), blood donation in the last 3 month Disease of the immune system (leucocytes <5000/μl) Application of immunomodulatory agents (Glucocorticoids, Antihistamine, Acetylsalicylic acid) Application of antithrombotic agents (Anticoagulant) Blood clotting disorders (abnormally levels of thrombocytes [<150.000, >450.000 ± 50 ], Partial thromboplastin time (PTT) [26-36 s ± 5 s], Quick [70-120% ± 10%]) or wound healing Thyroid disease (untreated hypothyroidism or hyperthyroidism, treatment with thiamazol) Epilepsy Application of drugs which can manipulate the thermoregulation (Antipsychotic) Rosacea Vitamine supplement (with the las 4 weeks) Cigarettes (or non-smokers <1 year) alcohol consumption (men> 30 g / d, women> 20 g / d), drug abuse Severe psychiatric illness or addiction Risk for/ or HIV or Hepatitis B or C Shift work or anormal circadian rhythm Muscle diseases, orthopedic restrictions Hypersensitivity to local anaesthetic Pregnancy, lactation Metallic and magnetic implants (for example, mechanical heart valves, joint prostheses, clip after vascular surgery, middle and inner ear implants or fresh dental implants) Claustrophobia Hypohidrosis Participation in another intervention study within the last 3 month
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michael Roden, Prof., MD
Phone
00492113382
Ext
201
Email
Michael.Roden@ddz.de
First Name & Middle Initial & Last Name or Official Title & Degree
Nina Saatmann, M.Sc.
Phone
00492113382
Ext
514
Email
Nina.Saatmann@ddz.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Roden, Prof., MD
Organizational Affiliation
German Diabetes Center
Official's Role
Study Director
Facility Information:
Facility Name
German Diabetes Center
City
Düsseldorf
State/Province
NRW
ZIP/Postal Code
40225
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Roden, Prof., MD
Phone
00492113382
Ext
201
Email
Michael.Roden@ddz.de
First Name & Middle Initial & Last Name & Degree
Nina Saatmann, M.Sc.
Phone
00492113382
Ext
514
Email
Nina.Saatmann@ddz.de

12. IPD Sharing Statement

Citations:
PubMed Identifier
31199953
Citation
Christiansen D, Eibye KH, Hostrup M, Bangsbo J. Blood flow-restricted training enhances thigh glucose uptake during exercise and muscle antioxidant function in humans. Metabolism. 2019 Sep;98:1-15. doi: 10.1016/j.metabol.2019.06.003. Epub 2019 Jun 12.
Results Reference
background
PubMed Identifier
22051111
Citation
Loenneke JP, Fahs CA, Rossow LM, Abe T, Bemben MG. The anabolic benefits of venous blood flow restriction training may be induced by muscle cell swelling. Med Hypotheses. 2012 Jan;78(1):151-4. doi: 10.1016/j.mehy.2011.10.014. Epub 2011 Nov 1.
Results Reference
background
PubMed Identifier
24149640
Citation
Abe T, Fujita S, Nakajima T, Sakamaki M, Ozaki H, Ogasawara R, Sugaya M, Kudo M, Kurano M, Yasuda T, Sato Y, Ohshima H, Mukai C, Ishii N. Effects of Low-Intensity Cycle Training with Restricted Leg Blood Flow on Thigh Muscle Volume and VO2MAX in Young Men. J Sports Sci Med. 2010 Sep 1;9(3):452-8. eCollection 2010.
Results Reference
background
PubMed Identifier
10846023
Citation
Takarada Y, Takazawa H, Sato Y, Takebayashi S, Tanaka Y, Ishii N. Effects of resistance exercise combined with moderate vascular occlusion on muscular function in humans. J Appl Physiol (1985). 2000 Jun;88(6):2097-106. doi: 10.1152/jappl.2000.88.6.2097.
Results Reference
background
PubMed Identifier
10642363
Citation
Takarada Y, Nakamura Y, Aruga S, Onda T, Miyazaki S, Ishii N. Rapid increase in plasma growth hormone after low-intensity resistance exercise with vascular occlusion. J Appl Physiol (1985). 2000 Jan;88(1):61-5. doi: 10.1152/jappl.2000.88.1.61.
Results Reference
background
PubMed Identifier
28259850
Citation
Hughes L, Paton B, Rosenblatt B, Gissane C, Patterson SD. Blood flow restriction training in clinical musculoskeletal rehabilitation: a systematic review and meta-analysis. Br J Sports Med. 2017 Jul;51(13):1003-1011. doi: 10.1136/bjsports-2016-097071. Epub 2017 Mar 4.
Results Reference
background
PubMed Identifier
29629973
Citation
Mattocks KT, Jessee MB, Mouser JG, Dankel SJ, Buckner SL, Bell ZW, Owens JG, Abe T, Loenneke JP. The Application of Blood Flow Restriction: Lessons From the Laboratory. Curr Sports Med Rep. 2018 Apr;17(4):129-134. doi: 10.1249/JSR.0000000000000473.
Results Reference
background
PubMed Identifier
30980151
Citation
Harreiter J, Roden M. [Diabetes mellitus-Definition, classification, diagnosis, screening and prevention (Update 2019)]. Wien Klin Wochenschr. 2019 May;131(Suppl 1):6-15. doi: 10.1007/s00508-019-1450-4. German.
Results Reference
background
PubMed Identifier
28270856
Citation
Pesta DH, Goncalves RLS, Madiraju AK, Strasser B, Sparks LM. Resistance training to improve type 2 diabetes: working toward a prescription for the future. Nutr Metab (Lond). 2017 Mar 2;14:24. doi: 10.1186/s12986-017-0173-7. eCollection 2017.
Results Reference
background
PubMed Identifier
30306467
Citation
Centner C, Wiegel P, Gollhofer A, Konig D. Effects of Blood Flow Restriction Training on Muscular Strength and Hypertrophy in Older Individuals: A Systematic Review and Meta-Analysis. Sports Med. 2019 Jan;49(1):95-108. doi: 10.1007/s40279-018-0994-1. Erratum In: Sports Med. 2018 Nov 9;:
Results Reference
background
Links:
URL
http://www.owensrecoveryscience.com
Description
Methode

Learn more about this trial

RESIST! Blood-flow Restriction Resistance Training for Improving Insulin Sensitivity in Type 2 Diabetes

We'll reach out to this number within 24 hrs